EPs 7630-solution--an effective therapeutic option in acute and exacerbating bronchitis.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/17184984
Conclusion of this study
The onset of action appeared after two days on average. Adverse events occurred in a total of 16 patients. There were no serious adverse events. Altogether, 78% of the patients were satisfied or very satisfied with the treatment.
Supplements analyzed in this study
|
Health conditions analyzed in this study
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
Functions related to this study
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
Body systems related to this study
Immune System |
Nervous System |
Respiratory System |